HD-Tdcs and Pharmacological Intervention For Delirium In Critical Patients With COVID-19

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

December 2, 2022

Study Completion Date

January 30, 2023

Conditions
COVID-19DeliriumCritical Illness
Interventions
COMBINATION_PRODUCT

Active HD-tDCS

Brain stimulation using active high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19

COMBINATION_PRODUCT

Sham HD-tDCS

Sham high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19

Trial Locations (1)

51051900

Federal University of Paraiba, João Pessoa

All Listed Sponsors
collaborator

City University of New York

OTHER

lead

Suellen Andrade

OTHER